✦ LIBER ✦

Suppressor T cells and the regression phase of syngeneic intradermally developing P-815 mastocytomas

✍ Scribed by Bertschmann, May; Schären, Beatrice; Lüscher, Ernst F.

Book ID: 122851406
Publisher: Elsevier Science
Year: 1982
Weight: 709 KB
Volume: 18
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(82)90013-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation of in Vivo and in Vitro Immu

Correlation of in Vivo and in Vitro Immune Reactions Against the Intradermally Developing P-815 Mastocytoma in the Syngeneic Mouse

✍ Bertschmann, May; Schären, Beatrice; Lüscher, Ernst F. 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 1011 KB

Preparation and properties of antisera d

Preparation and properties of antisera directed against antigens of the P-815 mastocytoma cell not shared by its syngeneic host, the DBA/2 mouse

✍ M. Bertschmann; K.J. Clemetson; E.F. Lüscher 📂 Article 📅 1976 🏛 Elsevier Science ⚖ 704 KB

Treatment of the P815 murine mastocytoma

Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells

✍ Brent A. Williams; Andrew P. Makrigiannis; Jonathan Blay; David W. Hoskin 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 122 KB 👁 2 views

We have investigated the effect of pre-treatment with the anti-cancer drugs cisplatin and etoposide on the susceptibility of P815 murine mastocytoma cells to lysis by murine spleen-derived anti-CD3-activated killer-T (AK-T) cells. A 20 hr pre-treatment with cisplatin (0.2-2 microg/ml) or etoposide (